Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.

In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go ...

KCAS Bio, a global provider of harmonized spectral flow cytometry, today announced ongoing developments in its service ...

Health technology company Seqster announced Thursday the launch of its new 1-Click Sites platform, tapping BioIVT as its ...

AWS's new AI platform grants researchers direct access to a broad library of biological foundation models for lab-in-the-loop drug discovery.

A new integrated service allows Tamarind Bio’s platform users to validate affinity and specificity of computationally designed binder predictions through A-Alpha Bio’s AlphaSeq platform.SAN FRANCISCO ...

BIO Asia–Taiwan 2026 Chairman Johnsee Lee highlighted three major features of this year's gathering. First, showcasing new ...

The platform offers AI models and agents that help scientists design, test and iterate experiments to identify and analyze ...

(Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment ...

Wallace Lin (林治華), secretary-general of the Taiwan Bio Industry Organization, said one of the biggest challenges in clinical ...

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of ...